According to Zhitong Finance App, Osecon (002755.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 881 million yuan, a year-on-year decrease of 13.54%; achieved net profit attributable to shareholders of listed companies of 121 million yuan, a year-on-year decrease of 24.6%; realized net profit attributable to shareholders of listed companies minus non-recurring gains and losses of 107 million yuan, a year-on-year decrease of 24.44%; basic earnings per share were 0.13 yuan.

During the reporting period, the company continued to increase investment in R&D of innovative drugs. During the reporting period, R&D expenses increased by 62.58% compared to the same period of the previous year, resulting in a decrease in the company's net profit during the reporting period compared to the same period last year. The company's innovative anti-tumor drugs were included in medical insurance and commercialized sales gradually, laying the foundation for the company's long-term development; at the same time, some anti-infective and chronic disease products were affected by the centralized procurement and price reduction policies of national and local alliances, and sales revenue for related products decreased year-on-year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.